Related News
China bans weight loss drug fenfluramine hydrochloride
Source: Xinhua |
January 8, 2009, Thursday
|
Online Edition
Online Edition
CHINA today banned the weight loss drug fenfluramine hydrochloride, citing adverse effects on humans.
China will stop the production, sale and use of the substance, in both material and product form, and revoke its approval, Yan Jiangying, spokeswoman with the State Food and Drug Administration, told a press conference.
The change took effect yesterday, she said.
Side-effects monitoring found the drug could harm the heart and pulmonary arteries and lead to bloody urine and nausea, Yan said. She said the risks outweighed the benefits it could bring.
She added that producers must recall their products and those who have bought the drug can ask for a refund from hospitals or drugstores.
The drug was banned in the United States and some European countries as early as 2000, according to Yan.
China will stop the production, sale and use of the substance, in both material and product form, and revoke its approval, Yan Jiangying, spokeswoman with the State Food and Drug Administration, told a press conference.
The change took effect yesterday, she said.
Side-effects monitoring found the drug could harm the heart and pulmonary arteries and lead to bloody urine and nausea, Yan said. She said the risks outweighed the benefits it could bring.
She added that producers must recall their products and those who have bought the drug can ask for a refund from hospitals or drugstores.
The drug was banned in the United States and some European countries as early as 2000, according to Yan.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
